RGC
VKTX icon

Roberts, Glore & Co’s Viking Therapeutics VKTX Stock Holding History

Roberts, Glore & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,540
Closed -$310K – 254
2026
Q1 		$310K Sell
9,540
-850
-8% -$27.3K 0.09% 169
2025
Q4 		$366K Sell
10,390
-300
-3% -$10.6K 0.1% 156
2025
Q3 		$281K Buy
10,690
+2,850
+36% +$85K 0.08% 176
2025
Q2 		$208K Buy
+7,840
New +$206K 0.06% 197

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Roberts, Glore & Co's VKTX Position: Q2 2026 in Review

Roberts, Glore & Co sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 9,540 shares — an estimated $310K sold.

Roberts, Glore & Co first reported a position in VKTX in Q2 2025 and held it in 4 quarters. The position peaked at $366K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Roberts, Glore & Co reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Roberts, Glore & Co sold 9,540 Viking Therapeutics shares in Q2 2026, an estimated $310K.
  • Roberts, Glore & Co first reported a position in Viking Therapeutics in Q2 2025 and held it in 4 quarters.
  • Roberts, Glore & Co's Viking Therapeutics position peaked at $366K in Q4 2025.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Roberts, Glore & Co's 13F filing for Q2 2026, filed 11 Aug 2026.